Skip to main content

Checking access...

Portfolio Strategy

AMRI

Walk-forward

Adaptive Macro Regime Index

Rebalancing
Daily
Universe
SPY / Cash
As of
...

The Strategy

AMRI (Adaptive Macro Regime Index) monitors macroeconomic conditions using Federal Reserve economic data and cross-asset signals. When the macro environment deteriorates beyond critical thresholds, the strategy exits equity exposure entirely and moves to cash. When conditions normalize, it re-enters.

This produces a binary allocation: either fully invested in the S&P 500 or fully in cash. The approach sacrifices some upside during extended rallies in exchange for avoiding the worst drawdowns.

Walk-Forward Test Active Starting December 14, 2025, this strategy is being tested with market data in a walk-forward framework. All historical data before this date represents backtested performance. The shaded region in the chart indicates the start of the walk-forward period.

How It Works

Each trading day, the model evaluates a composite of macroeconomic indicators sourced from the Federal Reserve Economic Database (FRED). These indicators are z-scored and aggregated into a single regime signal with publication-lag correction to prevent look-ahead bias.

When the composite signal crosses below the threshold, the strategy moves to cash. When it recovers above the threshold, the strategy re-enters SPY. The dashboard displays both backtested and live performance. The shaded area marks December 14, 2025, the start of the walk-forward test.

SPY / Cash
Universe
Binary
Long / Flat Signal
Daily
Rebalancing

Simulation Settings

Set your start date and initial capital to configure the model simulation. AMRI uses daily macro signals from FRED economic data. The backtest begins January 2005. Minimum capital: $20,000.

Model Performance

Drawdown

Peak-to-trough decline

Position History

SPY vs Cash over time
Model Value
--
--
YTD Return
--
SPY: --
Volatility
--
Sharpe Ratio
--
Excess return basis

Walk-Forward Performance

Since Dec 14, 2025
--
AMRI Return
--
SPY B&H Return
--
vs SPY B&H
--
Days Live

Current Signal

Composite Signal --
Position --
Days in Position --

Walk-Forward Status

Walk-forward testing started December 14, 2025

Daily rebalancing (signal evaluated each trading day)

Performance Metrics

Sortino Ratio
--
Downside risk-adjusted
Max Drawdown
--
Peak to trough
Calmar Ratio
--
Return/Max DD
Beta
--
vs SPY
VaR (95%)
--
Daily at risk
Exposure
--
Time in market
Up Capture
--
Bull market
Down Capture
--
Bear market
Win Rate
--
Profitable trades
Profit Factor
--
Gross profit / loss

Crisis Performance

Strategy behavior during major market downturns:

Crisis AMRI SPY
2008 GFC---55%
2020 Covid---34%
2022 Bear---25%

AMRI vs SPY Buy & Hold

Full backtest period comparison:

Metric AMRI SPY
Total Return----
CAGR----
Volatility----
Sharpe Ratio----
Max Drawdown----
Exposure--100%

Statistical Validation

Before deployment, AMRI was subjected to a multi-phase validation framework based on peer-reviewed statistical methods. All tests used the fixed production strategy without post-hoc parameter tuning.

Permutation Test passed
p < 0.001

10,000 random position sequences. None matched the observed risk-adjusted return.

Block Bootstrap passed
CI: 1.79 – 2.53

95% Sharpe ratio confidence interval from 10,000 bootstrap samples. Entirely above zero. Based on Politis & Romano (1994).

Parameter Robustness passed
100%

96 parameter combinations tested. All produced positive Sharpe ratios. Deployed at 79th percentile.

Regime Stability passed
All regimes

Positive risk-adjusted returns across bull/bear markets and high/low volatility environments.

Tail Risk passed
−2.7%

CVaR (95th percentile) per month vs −9.5% for SPY. Worst observed month: −4.0%.

Data Integrity verified
Verified

All inputs are market-based and final upon release. Publication lag applied to prevent look-ahead bias.

Validation based on White (2000), Politis & Romano (1994), Bailey & Lopez de Prado (2014). All tests conducted on the fixed production strategy. Past statistical performance does not guarantee future results.